SCHEMBL12901867

SCHEMBL12901867

CNS(=O)(=O)c1ccc(/N=N/c2ccccc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.61
MEN1 O00255 1/20 0.61
HPGD P15428 1/20 0.61
KMT2A Q03164 1/20 0.61
POLB P06746 1/20 0.58
CYP2D6 P10635 1/20 0.58
NR3C2 P08235 1/20 0.56
SMN1; SMN2 Q16637 3/20 0.53
GAA P10253 1/20 0.53
CYP19A1 P11511 1/20 0.53
CA12 O43570 3/20 0.52
CA2 P00918 3/20 0.52
CA9 Q16790 3/20 0.52
CA1 P00915 2/20 0.52
CA3 P07451 2/20 0.52
CA4 P22748 2/20 0.52
CA6 P23280 2/20 0.52
CA5A P35218 2/20 0.52
CA7 P43166 2/20 0.52
CA13 Q8N1Q1 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18580 0.81 NR3C2 (0.64) MEN1KMT2ANR3C2SMN1; SMN2GAA
SCHEMBL9888564 0.80 F2 (0.66) MAPTMEN1KMT2APOLBSMN1; SMN2
Dimethylamine SCHEMBL7701402 0.79 POLB (0.56) MAPTMEN1HPGDKMT2APOLB
Hydrochloric Acid SCHEMBL1807459 0.79 NR3C2 (0.62) MEN1KMT2ANR3C2SMN1; SMN2GAA
Water SCHEMBL27466609 0.79 NR3C2 (0.62) MEN1KMT2ANR3C2SMN1; SMN2GAA
Hydrogen Sulfide SCHEMBL27690671 0.79 NR3C2 (0.62) MEN1KMT2ANR3C2SMN1; SMN2GAA
SCHEMBL11514359 0.79 NR3C2 (0.62) MEN1KMT2ANR3C2SMN1; SMN2GAA
SCHEMBL7629070 0.78 SMN1; SMN2 (0.80) NR3C2SMN1; SMN2GAACA12CA2
SCHEMBL3906959 0.78 NR3C2 (0.61) MAPTMEN1KMT2ANR3C2SMN1; SMN2
SCHEMBL27094281 0.77 POLB (0.69) MAPTMEN1HPGDKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140378326-A1 Methods, Kits and Compositions Pertaining to the Suppression of the Detectable Probe Binding to Randomly Distributed Repeat Sequences Genomic Nucleic Acid DAKO DENMARK APS (DK) 2014-12-25 US disclosed
US-8754191-B2 Methods, kits and compositions pertaining to the suppression of the detectable probe binding to randomly distributed repeat sequences genomic nucleic acid BOSTON PROBES, INC. (US) 2014-06-17 US disclosed
US-20130150264-A1 Methods, Kits and Compositions Pertaining to the Suppression of the Detectable Probe Binding to Randomly Distributed Repeat Sequences Genomic Nucleic Acid Life Technologies Corporation (US) 2013-06-13 US disclosed
US-20110306520-A1 Methods, Kits and Compositions Pertaining to the Suppression of the Detectable Probe Binding to Randomly Distributed Repeat Sequences Genomic Nucleic Acid Life Technologies Corporation (US) 2011-12-15 US disclosed
US-7884053-B2 Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation BOSTON PROBES, INC. (US) 2011-02-08 US disclosed
US-7851155-B2 Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation BOSTON PROBES, INC. (US) 2010-12-14 US disclosed
US-20100190660-A1 Methods, Compositions And Libraries Pertaining To PNA Dimer And PNA Oligomer Synthesis BOSTON PROBES, INC. (US) 2010-07-29 US disclosed
US-7745126-B2 Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation BOSTON PROBES, INC. (US) 2010-06-29 US disclosed
US-7674585-B2 Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation BOSTON PROBES, INC. (US) 2010-03-09 US disclosed
US-7638279-B2 Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation BOSTON PROBES, INC. (US) 2009-12-29 US disclosed
US-7605253-B2 Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation BOSTON PROBES, INC. (US) 2009-10-20 US disclosed
US-7566420-B1 Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation BOSTON PROBES, INC. (US) 2009-07-28 US disclosed
US-20090163381-A1 Methods, Kits and Compositions Pertaining to Combination Oligomers and Libraries for Their Preparation APPLERA CORPORATION. (US) 2009-06-25 US disclosed
US-20080269074-A1 Methods, Kits and Compositions Pertaining to Combination Oligomers and Libraries for Their Preparation APPLERA CORPORATION (US) 2008-10-30 US disclosed
US-20080220987-A1 Methods, Kits and Compositions Pertaining to Combination Oligomers and Libraries for Their Preparation APPLERA CORPORATION. (US) 2008-09-11 US disclosed
US-20080206747-A1 Methods, Kits and Compositions Pertaining to Combination Oligomers and Libraries for Their Preparation APPLERA COPORATION (US) 2008-08-28 US disclosed
US-20080125332-A1 Methods, Kits and Compositions Pertaining to Combination Oligomers and Libraries for Their Preparation APPLERA CORPORATION. (US) 2008-05-29 US disclosed
US-20080085837-A1 Methods, Kits and Compositions Pertaining to Combination Oligomers and Libraries for Their Preparation APPLERA CORPORATION (US) 2008-04-10 US disclosed
US-20070105145-A1 Methods, Kits and Compositions Pertaining to Combination Oligomers and Libraries for Their Preparation APPLERA CORPORATION (US) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190660-A1 Methods, Compositions And Libraries Pertaining To PNA Dimer And PNA Oligomer Synthesis NCL, RNGTT, SSB MAPT 1205/4885MEN1 3323/4885HPGD 3619/4885
US-20110306520-A1 Methods, Kits and Compositions Pertaining to the Suppression of the Detectable Probe Binding to Randomly Distributed Repeat Sequences Genomic Nucleic Acid UNG, RNGTT, DNTT MAPT 2649/4885MEN1 2339/4885HPGD 4825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.